Clinical Trials Browser

Phase 2/3 × INDUSTRY × rubitecan × Clear all

NCT00113256 2024-08-02

Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer

Phase 2/3 Terminated

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms